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Abstract
Transfer RNAs (tRNAs) are essential for protein synthesis and translation fidelity. Some human
tRNA variants may cause amino acid misincorporation: tRNAGly variants (tRNAGlyCCC,
tRNAGlyGCC) have mutations that generate an alanine tRNA identity element (G3:U70), likely
causing mis-aminoacylation of glycine tRNAs with alanine, while the tRNAAlaAGC G35C
(tRNAAlaACC) variant may function similarly to mis-incorporate Ala at Gly codons by generating
a Gly anticodon. I propose that these mistranslating tRNAs will disrupt protein homeostasis in
mammalian cells. Although the tRNAGly and tRNAAla variants did not affect protein synthesis in
normal growth conditions, tRNAGlyGCC A3G depressed protein synthesis following proteasome
inhibition. Mass spectrometry confirmed Ala mistranslation at multiple Gly codons caused by the
tRNAGlyGCC A3G and tRNAAlaAGC G35C variants. Multiple mistranslation events were also
observed within the same peptide. These data reveal mistranslation of Ala at Gly codons that is
caused by natural human tRNA variants and tolerated under normal conditions.
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Summary for Lay Audience
Transfer RNAs (tRNAs) are responsible for bringing the correct amino acid to the site of protein
production in cells. Each amino acid has its own set of tRNAs and an enzyme, called an aminoacyltRNA synthetase (aaRS) that specifically recognizes both the tRNA and amino acid to link them
together. aaRS recognize tRNAs through sequences unique to tRNAs for that amino acid. Most
tRNAs are recognized by their anticodon, a sequence in the tRNA that determines which amino
acid goes where in the protein and is complementary to a codon or set of codons found in the
messenger RNA (mRNA). However, some aaRS recognize features of the tRNA outside the
anticodon. For example, to attach the amino acid alanine to its tRNAs, the alanine-aaRS recognizes
the tRNA solely by the presence of a unique G3:U70 base pair close to the site of amino acid
attachment in the tRNA and does not recognize the anticodon at all. For tRNAs that carry glycine,
the anticodon is essential for attaching the amino acid to glycine tRNAs. Specific recognition
requirements in tRNAs may allow for mutations to occur outside of unique recognition sequences
that would cause them to mis-incorporate amino acids into proteins. Amino acid misplacement can
cause proteins to misfold, be degraded, or build-up, leading to further problems within the cell. I
studied three different tRNAs that could incorrectly place the amino acid alanine instead of glycine
into proteins, a process called mistranslation. Through expression of a fluorescent protein
alongside mistranslating tRNAs, I determined that glycine to alanine mistranslation does not have
a significant negative impact on protein levels in mammalian cells under normal conditions. When
cells were unable to degrade proteins, expression of one glycine to alanine mistranslating tRNA
decreased protein levels compared to wild-type tRNA expression. I determined sites of amino acid
mutations in protein isolated from mistranslating cells to conclude that mistranslating tRNA
expression caused amino acid misincorporation. However, the mistranslation was conservative
enough to not disrupt normal protein production in cells. My findings show that glycine to alanine
mistranslation in mammalian cells is not toxic under normal conditions.
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Chapter 1

1

Introduction

1.1

The Central Dogma

The central dogma of biology describes the transfer of genetic instructions stored in
deoxyribonucleic acid (DNA) to allow for synthesis of proteins required for cellular
function and maintenance. The central dogma was first proposed by Francis Crick in 1958
following the discovery of DNA structure in 1952 by Rosalind Franklin [1] and later by
Watson and Crick [2]. Along with the deciphering of the genetic code in 1964 [3], the
central dogma has become the foundational framework of understanding biological
processes. We now appreciate that in order for a protein to be made in the cell, DNA from
the corresponding protein coding gene must undergo transcription, generating a ribonucleic
acid (RNA) intermediate called messenger RNA (mRNA), that will be translated into a
protein by the ribosome. The central dogma states that transfer of information can go from
DNA to RNA and back, but cannot be extracted from a protein’s amino acid sequence to
determine the original DNA sequence from which it originated [4].
DNA stores the genetic information for all living organisms. The genetic alphabet consists
of four letters (A, C, G, T) that make up the countless genes needing to be deciphered into
proteins to enable a functional cell. mRNA was identified as that intermediate between
DNA and proteins, carrying the code to be read by translation machinery and produce
proteins in the cell [5].
Proteins are encoded in DNA as genes, which are transcribed into mRNA by RNA
polymerase II. Following splicing and post-transcriptional modification [6], mRNA
transcripts are then ready to be translated into a chain of amino acids by the ribosome, and
eventually folded into functioning molecules in the cell [7]. For this to happen, there must
exist a carrier molecule bringing the correct amino acid to the translation machinery for a
protein to be made. Transfer RNAs (tRNAs) are integral to normal cell function as they are
essential components of the protein synthesis machinery. In all cells, the 20 proteinogenic
amino acids are incorporated into proteins following their specific ligation to a family of
1

tRNAs [8]. The existence of tRNAs was first proposed in 1955 as a set of adaptor molecules
that link nucleic acid sequences to the protein sequences they encode [9]. Shortly thereafter,
tRNAs were discovered that functioned as the hypothesized adaptors to carry amino acids
to the ribosome for protein production [10]. The discovery of tRNAs was essential to
deciphering the genetic code [3, 11].

1.2

tRNA transcription and structure

tRNA genes are transcribed by RNA polymerase III. The resulting tRNA transcript then
undergoes a series of cleavages and post-transcriptional modifications to become a mature
tRNA (reviewed in [12]). Mature tRNAs are composed of 73 to 90 nucleotides that are
arranged into 4 or 5 base-pairing stems and connecting loops [13]. In three dimensions,
tRNAs fold into L-shaped structures with the anticodon and amino acid acceptor site on
opposite ends. The acceptor stems contain a conserved 3’-CCA sequence that is necessary
for ligation, catalyzed by a specific aminoacyl tRNA synthetase (aaRS), of the amino acid
to the 3’-terminal A76 onto each tRNA [14] (Fig. 1). The anticodon loop of a tRNA
contains three central nucleotides (bases 34, 35, and 36) that read a codon or set of codons
found in mRNA sequences. The anticodon recognizes its appropriate codon through
normal base pair interactions or wobble pairing with codons in an mRNA bound to a
translating ribosome. Thus, properly aminoacylated tRNAs are essential for accurate
translation of the proteome.

1.3

tRNA role in protein translation

tRNAs act as intermediate molecules between mRNA and protein: they are required to
bring the appropriate amino acid to the site of protein production at the ribosome. For a
protein to be accurately translated, the ribosome must recognize the mRNA, after which it
can begin the three-step process of translation: initiation, elongation, and termination.
The ribosome is composed of two subunits, small and large [15, 16]. The large subunit is
responsible for tRNA incorporation to allow for protein production, consisting of three
sites for tRNA incorporation: A (acceptor), P (peptidyl), and E (exit) [15-18]. After
recognition of an mRNA, initiation of translation begins with the first codon to be read,
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usually the start codon AUG, which codes for methionine (Met). An aminoacylated MettRNAMet enters the P-site of the ribosome, where the tRNA anticodon and mRNA codon
are paired, and an aminoacylated tRNA for the next amino acid to be decoded enters the A
site. At the peptidyl-transfer center in the ribosome, a peptide bond is formed between the
amino acids in the A- and P-sites of the ribosome, then the tRNA in the P-site releases the
amino acid, Met, and the entire complex moves along the mRNA to the next codon. The
tRNAMet in the P-site is now in the E-site, awaiting release from the ribosome upon
acceptance of a new tRNA into the A-site, and the entire process of tRNA movement in
the ribosome from A- to P- to E-site is then repeated during the elongation phase. As
elongation is happening, the peptide chain begins to fold into its native conformation.
When one of three stop codons is reached, a release factor binds to the stop codon, signaling
translation termination and release of the nascent peptide chain, which completes its
folding into a functional protein (reviewed in [7]).
In cells, high translational fidelity is essential to maintain error-free protein production.
However, amino acid misincorporation in eukaryotes occurs at a rate of approximately 1
in every 10,000 amino acids. Calculations estimate that such an error rate would lead to
roughly 15% of all proteins translated in a cell having at least one mistranslated amino
acid, in standard growing conditions [19, 20]. Recent studies suggest that the translational
error rate is actually much lower, citing that it potentially occurs as low as 10–6, depending
on mRNA codon and tRNA anticodon pairing [21, 22]. The level or rate of mistranslation
has the potential to be increased depending on the presence of mistranslating tRNA variants
in the genome [23, 24].

1.4

tRNA-dependent mistranslation

Mistranslation of proteins is a phenomenon in cells that causes incorporation of incorrect
amino acids into proteins. The wrong amino acid can be incorporated in proteins that have
mutations to the protein’s coding gene which cause singular amino acid substitutions
within the specific protein that is coded incorrectly. However, if mutations arise in aaRS
genes, it may allow for misincorporation of amino acids in multiple proteins within the cell
[25]. In order for tRNAs to become substrates for protein synthesis, aaRS enzymes must
recognize the cognate tRNA and amino acid to facilitate a two-step, ATP-dependent
3

reaction that ligates the amino acid to its cognate tRNA (reviewed in [26]). Although some
aaRS enzymes are equipped with editing features that allow for clearance of mis-charged
tRNAs due to incorrect recognition of the cognate amino acid [20, 27], if an aaRS enzyme
gene is mutated, that ability may be hindered and can cause disease in the individual.
Charcot-Marie-Tooth disease (CMT) is a hereditary disease that causes motor and sensory
neuropathy, and its cause is linked to mutations in multiple aaRS enzymes (reviewed in
[28]). Mutations to aaRS enzymes associated with CMT lead to loss- or gain-of-function
by the enzyme that may hinder the enzyme’s ability to aminoacylate cognate tRNAs or
inhibit protein translation [28-30]. Despite the amount of research on aaRS-mediated
mistranslation, emerging research shows that variant tRNA genes present in the population
also have the potential to facilitate mistranslation and potentially modify disease [23, 24,
31].
Here, we studied mistranslation caused directly by tRNAs, which place the amino acid in
the peptide chain. Identity elements are nucleotides present in a tRNA sequence that are
required for recognition by the cognate aaRS. Although many tRNAs are distinguished
through anticodon recognition by a cognate aaRS enzyme, most tRNAs require additional
or separate identity elements for recognition [32]. For example, the G3:U70 base pair found
in the acceptor stem of alanine tRNAs (tRNAAla) is the major determinant for alanyl-tRNA
synthetase (AlaRS), where the AlaRS enzyme recognizes tRNAAla independent of the
tRNA anticodon [33]. Seryl-tRNA synthetase (SerRS) [34] and pyrrolysyl-tRNA
synthetase [35] also do not recognize the tRNA anticodon, while in some species leucyltRNA synthetase recognizes only the middle base (G35) of the anticodon as an important
recognition element [36].
Among the plethora of natural human tRNA variants [24] are mutant tRNAs with altered
anticodon sequences, not required for recognition by the cognate aaRS, which will not
affect aminoacylation, but may alter the codon(s) decoded by a particular tRNA, resulting
in mistranslations across the proteome. Further, tRNAs recognized by their anticodon could
sustain a mutation elsewhere in their sequences that may result in the creation of an identity
element for a non-cognate aaRS [37]. Depicted in Fig. 1 is the proposed mechanism of
mistranslation caused by the alanine and glycine tRNAs described and studied here.
4

tRNAAla sustains an anticodon mutation that allows decoding of glycine codons in mRNA.
Both glycine tRNA variants acquire the alanine tRNA identity element, G3:U70, allowing
recognition by AlaRS and aminoacylation with alanine. The alanine-charged glycine
tRNAs (Ala-tRNAGly) then supply alanine to the ribosome when decoding glycine codons
in mRNA.
tRNA-dependent mistranslation was previously shown using a mistranslating proline (Pro)
tRNA variant that places Ala at Pro codons through an A3G mutation in the tRNAPro
acceptor stem to create the G3:U70 tRNAAla identity element described above [37].
Similarly, a mistranslating serine (Ser) tRNA variant with an anticodon mutation, G35A,
that decodes phenylalanine (Phe) codons with Ser [31] was characterized and is used as a
positive control throughout the work described here. Due to the established effects of
tRNASerAAA on protein synthesis and cytotoxicity, I used the wild-type and variant tRNASer
as positive controls for effects of tRNA-dependent protein mistranslation, where the
tRNASerAAA causes decreased protein synthesis and increased cytotoxicity [31].

A

B
Ala

Ala

Ala-tRNAAlaACC

Ala-tRNAGlyC/GCC A3G:U70

ribosome
3’-

CCA

5’-

-5’

GGU -3’
Gly

3’-

CC C/G

-5’

5’- GGG/C/U -3’

Gly

mRNA

Figure 1: Schematic of tRNA-dependent mistranslation mechanisms placing Ala at
Gly codons. (A) The naturally occurring tRNAAla G35C variant (red circle) acquires a Gly
anticodon (tRNAAlaACC) and decodes Gly codons, including GGU, as indicated, with Ala.
(B) The natural human tRNAGlyC/GCC A3G variants (red circle) acquire the G3:U70 major
identity element for AlaRS. The Ala accepting tRNAGly also decodes the indicated Gly
codons with Ala.

5

1.5

tRNAs can modify disease

tRNAs, like other nucleic acids, are not exempt from mutation. Some mutations in tRNAs
can cause loss or gain of function [31, 38]. Initially, data from the 1000 Genomes Project
suggested that individuals carry 1 or 2 tRNA gene variants compared to the reference
genome [24, 39]. Targeted and deep sequencing efforts increased coverage of all human
tRNA genes to show that individuals have 60–70 tRNA variants compared to reference
[23], including both common and rare tRNAs with strong potential to cause mistranslation
in the cell. The existence of natural tRNA variants with potential to cause mistranslation is
emerging rapidly [31], yet nearly all human tRNA variants remain uncharacterized. Our
lab recently characterized a tRNASerAGA G35A variant that occurs in ~3% of the population
and causes serine misincorporation at phenylalanine codons in mammalian cells. The data
showed that a single tRNA variant inhibited protein synthesis, increased cytotoxicity, and
inhibited degradation of huntingtin protein aggregates in a cellular model of
neurodegenerative disease [31]. The study demonstrates that natural tRNA variants can
cause amino acid misincorporation and phenotypic defects in cells. These results prompted
us to continue investigation of naturally occurring human tRNA variants to determine if all
mistranslating tRNAs cause similar phenotypes in mammalian cells.

1.6

ALS-associated FUS protein

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by protein
aggregate accumulation in the cytoplasm of motor neurons [40]. The disease manifests as
muscle stiffness and twitches, gradual increase of muscle weakness and muscle wasting,
before developing into loss of the ability to eat, speak, and move, eventually leading to loss
of breathing ability [40]. Many proteins are associated with ALS, such as C9orf72
(chromosome 9 open reading frame 72), SOD1 (superoxide dismutase 1), TDP-43 (TAR
DNA binding protein 43), and FUS (fused in sarcoma) [40]. The fused in sarcoma (FUS)
protein is responsible for RNA binding, transcriptional activation, and DNA repair in the
nucleus [41]. FUS has a nuclear localization signal sequence in its C-terminus that is
responsible for the protein’s localization to the nucleus following its translation in the
cytoplasm [42]. Disturbances to the localization signal impair the ability of FUS to locate
to the nucleus from the cytoplasm, causing FUS aggregation and accumulation in the
6

cytoplasm of motor neurons, leading to ALS in patients with localization sequence
mutations [42, 43]. We studied FUS with an R521C mutation in a cellular model for ALS,
alongside expression of a wild-type or mistranslating tRNA variant that is present in ~3%
of individuals [23, 31]. Due to the high prevalence of the tRNASer G35A variant, we
hypothesized that the coincidence of a mistranslating tRNA allele with a causative allele
for ALS would exacerbate cell toxicity (Lant et al, under review). We compared the
previously mentioned wild-type tRNASerAGA and mistranslating tRNASerAAA effects on
protein synthesis, cytotoxicity, and protein aggregation in N2a cells co-expressing wildtype or ALS-causative FUS in order to determine the role of tRNA-dependent
mistranslation in disease modification.

1.7

Hypothesis and goals

I investigated three tRNAs identified in publicly available sequencing databases. The
tRNAAlaAGC, tRNAGlyCCC, and tRNAGlyGCC variants (Table 1) each have the potential to
mistranslate alanine at glycine codons through either anticodon or identity element
mutations. The goal of my project is to determine whether these tRNAs enable amino acid
misincorporation and to measure their impact on protein synthesis, protein degradation,
and cell fitness.
I hypothesize that global mistranslation of alanine at glycine codons will disrupt protein
homeostasis in mammalian cells. I tested this hypothesis in three aims:
1. Clone tRNAs of interest and relevant variants for expression in mammalian cells.
2. Characterize the effects of variant tRNA expression and mistranslation on cell
viability and cytotoxicity under normal and stress conditions.
3. Assay the impact of mistranslation coupled with protein aggregation in a cellular
model of neurodegenerative disease.

7

Chapter 2

2

Materials and Methods

2.1

Cloning and plasmid purification

Genomic DNA from human embryonic kidney 293T (HEK 293T) cells was used to amplify
the tRNA genes of interest via polymerase chain reaction (PCR) following the Pfu Ultra II
polymerase protocol (Agilent; California, USA). Primers were designed to amplify 500
base pairs (bp) up and downstream of tRNA genes of interest. PCR products were separated
on a 1.5% agarose gel and visualized with ethidium bromide using a ChemiDoc MP
(BioRad; California, USA). Product bands were excised, purified using the Geneaid Gel
Extraction Kit (Geneaid; Taiwan, R.O.C), then used as templates for subsequent PCR
reactions. For wild-type tRNAs, a second round of PCR was performed using primers
designed to capture 300 bp up and downstream of the tRNA gene. PciI or NcoI restriction
sites were added to the 5’-end of each primer to allow for PciI or NcoI (New England
Biolabs; Massachusetts, USA) digestion and subsequent ligation into the PciI site on
pPANcherry using T4 DNA ligase (NEB). We constructed pPANcherry by removing the
EGFP gene (using SpeI and NheI restriction sites and re-ligation) from the EGFP-mCherry
construct in WT-PAN (Addgene # 99638; Massachusetts, USA). Integrating the tRNA
variants into pPANcherry, thus, enables mCherry to serve as a marker for transfection and
protein synthesis levels in individual cells. Mutant tRNAs were synthesized by overlap
extension PCR using first-round products as template as before [31]. Mutant tRNA genes
were amplified as half molecules, where the mutation was incorporated in overlapping 5’
ends of the primers (Table B1). The two overlapping tRNA halves were then used as
templates in a second round of PCR, amplifying the full-length mutant tRNA including
300 bp of up and downstream native sequence. These full-length mutant tRNA alleles were
then cloned into the PciI site of pPANCherry as above. All plasmids were verified by DNA
sequencing (Azenta US; Indianapolis, USA).
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2.2

Mammalian cell culture, transfection, and fluorescence
microscopy

Cell culture experiments were performed in HEK 293T (ATCC # CRL-3216) or mouse
neuroblastoma Neuro2a (N2a; ATCC #CCL-131) cells as indicated. Cells were grown and
maintained at 37C, with 5% CO2 and humidity. Cells were cultured in Dulbecco’s
modified Eagle medium (DMEM 4.5 g/L; Gibco) supplemented with 10% fetal bovine
serum (FBS; Gibco by Life Technologies) and 1% penicillin-streptomycin (P: 100 IU/mL;
S: 100 µg/mL; Wisent Bioproducts, Quebec, Canada). Plasmid transfections were
performed using Lipofectamine 3000 (Invitrogen, ThermoFisher Scientific, Massachusetts,
USA). In brief, for a 96-well plate transfection, 0.2 µL of p3000 reagent was mixed with
100 ng of plasmid DNA and DMEM containing no FBS or antibiotics, and 0.2 µL of
Lipofectamine reagent was mixed with DMEM (no FBS/antibiotics) in separate 1.5 mL
microcentrifuge tubes. The solutions were incubated at room temperature for 5 minutes,
mixed together, and vortexed. Following another 20-minute incubation at room
temperature, 10 µL of the mixture was pipetted into a single well and the cells were
incubated at 37C with 5% CO2 and humidity for 24 hrs before capturing fluorescent
images. All fluorescent images were taken using the EVOS FL Auto Imaging System
(ThermoFisher). mCherry fluorescence was visualized using the EVOS LED RFP light
cube (excitation 531  40 nm; emission 593  40 nm). After plating and transfection, cells
were incubated at 37C with 5% CO2 and humidity. Images were captured 24 hrs posttransfection and the level of mCherry fluorescence per cell was determined using a custom
Image J script as before [31].

2.3

Cytotoxicity and proteasome inhibition assays

All cytotoxicity and proteasome inhibition assays were done with at least N = 3 biological
replicates for each cell line and condition in 96-well plates. At 24-hours post-transfection
with plasmids containing a tRNA variant and mCherry, cell media was replaced with media
containing 0 or 10 M proteasome inhibitor (MG132, Sigma-Aldrich), and cells were
incubated at 37C for 4 hours before images were captured using the EVOS microscope.
Cytotoxicity was measured with the CytotoxGlo assay (Promega; Wisconsin, USA).
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Following the manufacturer’s instructions, 50 µL of assay reagent were added to each well
and an initial luminescence reading was taken using the Synergy H1 Plate Reader (BioTek;
Vermont, USA) before 50 L of assay buffer including digitonin was added to each well
and a final luminescence reading was taken. The initial luminescence reading quantifies
the population of dead cells in each well as a result of wild-type or mutant tRNA
expression, and the addition of digitonin allowed a determination of the total number of
cells present in each well. A ratio of the initial luminescent reading (number of dead cells
in a well) over the final luminescence reading (total number of cells in the same well)
allows the quantification of dead cell percentage present in each well caused by tRNA
expression.

2.4

Cell harvesting and lysis

Cells were plated and transfected in 6-well plates as described above. Media was replaced
24-hours post-transfection, and cells were incubated for an additional 24-hours before
harvesting. To harvest the cells, media was aspirated, and cells were incubated for 10
minutes at room temperature in 1 phosphate buffered saline (PBS; 137 mM NaCl, 2.7
mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) supplemented with 10 mM
ethylenediaminetetraacetic acid (EDTA). Then, cells were resuspended and transferred to
sterile 1.5 mL microcentrifuge tubes and centrifuged at 300  g for 5 minutes. Supernatant
was aspirated from cell pellets, which were stored at -80 C. Cell lysis was performed on
ice: 40 µL of mammalian cell lysis buffer (50 mM Na2HPO4, 1 mM Na4P2O7, 20 mM NaF,
2 mM EDTA, 2 mM EGTA, 1 mM Triton X-100, 1 mM dithiothrieitol, 0.3 mM
phenylmethylsulfonyl fluoride, and 1 tablet/10 mL complete mini EDTA-free Protease
Inhibitor Cocktail) [44] were added to each tube and cell pellets were resuspended before
centrifugation at 21.1  g for 10 minutes at 4C. Supernatants were transferred to sterile
1.5 mL centrifuge tubes. The Pierce bicinchoninic acid (BCA) assay (ThermoFisher) was
used to determine lysate protein concentrations to calculate appropriate loading volumes
for western blotting.
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2.5

Western blotting

Following harvest and lysis of cells, 15 g of protein from each lysate was separated using
sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE; 15%
acrylamide, 120 volts for 3 hours). Proteins were transferred from gel to methanolactivated polyvinylidene difluoride (PVDF) membranes using a Trans-Blot Turbo transfer
system (25 V, 1.3 A, 14 minutes; BioRad, California, USA). All blocking and wash
solutions were made using tris-buffered saline (TBS; 50 mM Tris-HCl, pH 7.5, 150mM
NaCl). Following transfer, membranes were incubated in blocking solution (3% bovine
serum albumin, 0.1% Tween-20, 1 TBS) for one hour at room temperature. Membranes
were then incubated overnight at 4C in primary antibody at dilutions of 1:1000 for antimCherry (AbCam; ab213511) or 1:5000 for anti-GAPDH (Sigma-Aldrich; MAB374). The
following day, membranes were washed in 1% BSA TBS-Tween 3  10 minutes, before a
2-hour incubation at room temperature in IRDye 800CW donkey anti-rabbit (mCherry; LiCor Inc, 926-32213) or IRDye 680RD goat anti-mouse (GAPDH; Li-Cor Inc, 926–68070)
fluorescent secondary antibodies at dilutions of 1:10,000. Membranes were then washed 3
 10 minutes in TBS-Tween, and once in 1 TBS for ten minutes before imaging.
Membranes were imaged using fluorescence on a ChemiDoc MP imager (Bio-rad).

2.6

Protein purification and mass spectrometry

N2a cells were plated and transfected with plasmids containing mCherry and wild-type
tRNAAlaAGC, tRNAAlaACC variant, or tRNAGlyGCC A3G variant in 10 cm plates as described
above with N = 3 biological replicates. At 24 hrs post transfection, cells were harvested
and stored in -80 C prior to use. Cells were lysed and mCherry was purified from cell
lysates through immunoprecipitation using the RFP-Trap Agarose kit (Chromotek,
Munich, Germany). Agarose beads coupled with RFP nanobodies allowed for affinity
purification of mCherry. The mCherry:agarose-bead complex was diluted with 2  sodium
dodecyl sulphate (SDS)-running buffer, boiled to detach the protein from the agarose
beads, and purified mCherry was separated using SDS-polyacrylamide gel electrophoresis
(PAGE) with 10% acrylamide. After separation of the protein, gels were stained with
Coomassie blue dye. The bands corresponding to mCherry were identified at 37 kDa,
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excised from the gel, placed in sterile 1.5 mL centrifuge tubes containing 5% acetic acid,
and submitted for mass spectrometry analysis at the Biological Mass Spectrometry
Laboratory (The University of Western Ontario, London, Canada). Concentration of
protein was not measured prior to mass spectrometry analysis as the protein was not
purified from the excised gel band prior to sample submission. Trypsin was used to digest
mCherry and the Orbitrap Elite Velos Pro mass spectrometer (ThermoFisher) was used in
FT/IT/CID configuration to identify amino acids mis-incorporated in mCherry as described
before [45]. Hits corresponding to Ala misincorporation at Gly codons (Gly + 14.02 = Ala)
were selected to only include peptides with an ion intensity of >1%.

2.7

Semi-denaturing detergent agarose gel electrophoresis (SDDAGE)

Cell lysates were prepared, and protein concentrations were measured 72 hrs posttransfection as described above. A 1.5% agarose gel and Tris-acetate EDTA (TAE) running
buffer containing 40 mM Tris-acetate, 1 mM EDTA, and 0.1% w/v SDS were prepared
according to established protocols [46]. Lysate samples containing 20 μg of protein were
diluted in 3  loading dye (0.5 M Tris-HCl, pH 6.8, 1.12 M sucrose; 0.025% w/v
bromophenol blue; 3.8% w/v SDS) with sterile milliQ H2O. Lysates were separated on the
agarose-SDS gel for at least 3 hours at 120V. Proteins were transferred to a PVDF
membrane by capillary gel transfer overnight using TAE with 0.1% SDS as a buffer.
mCherry-tagged FUS aggregates were visualized by western blotting with an α-mCherry
antibody.
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Chapter 3

3

Results

3.1

Identifying mistranslating tRNAs

The human tRNA genes tRNAAlaAGC (Ala-AGC-6-1), tRNAGlyCCC (Gly-CCC-1-1), and
tRNAGlyGCC (Gly-GCC-1-5) each have naturally occurring variants in the population with
the potential to mistranslate Gly codons with Ala (Table 1). Alanyl-tRNA synthetase
(AlaRS) recognizes the G3:U70 base pair of tRNAAla as the major identity determinant.
Since AlaRS does not ‘read’ the tRNAAla anticodon [33], mutations to the tRNAAla
anticodons are likely to cause mistranslation. We identified a common G35C variant in the
human tRNAAlaAGC 6-1 gene (tRNAAlaACC) that occurs in more than 6% of individuals. This
mutation is expected to retain Ala accepting activity while the ACC anticodon will decode
Gly instead of Ala codons.
Conversely, glycyl-tRNA synthetase (GlyRS) recognizes the tRNAGly anticodon and
normally requires the C35 and C36 bases of the anticodon, the A73 discriminator base, and
the C2:G71 base pair in the acceptor stem for glycylation of the tRNA [47]. Thus, while
tRNAGly anticodon mutations are likely to lead to loss of function, mutations at other sites
can create identity elements for other tRNAs in the sequence [32]. Some tRNAGly
sequences naturally have a U70 base, and we identified two different tRNAGly variants with
an A3G mutation. The A3G mutation produces a tRNAGly with a G3:U70 base pair, an
AlaRS identity element, and is expected to be an efficient Ala acceptor that retains its
ability to decode Gly codons. The A3G mutation occurs commonly (>5% allele frequency)
in the tRNAGlyCCC 1–1 gene and in a smaller but still substantial population (~1% of
individuals) in the tRNAGlyGCC 1–5 gene (Table 1). Each of these tRNAAlaACC and tRNAGly
A3G variants, thus, have potential to cause Ala mis-incorporation at Gly codons.
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Table 1: Naturally occurring tRNA variants characterized in this study
AA misincorporated

allele
frequency
[23]

allele
frequency
[24, 39]

Gly GGU/C/A

Ala

8.5%

6.5%

A3G

Gly GGG

Ala

5.2%

n.d.

Gly-GCC-1–5

A3G

Gly GGC/U

Ala

1.2%

1.2%

Ser-AGA-2–3

G35A

Phe UUU/C

Ser

3.0%

1.8%

tRNA Gene
[48]

tRNA variant

Ala-AGC-6–1

G35C

Gly-CCC-1–1

codons
read

n.d. – not detected

3.2

Protein synthesis in mistranslating cells

Inhibited protein synthesis is a hallmark response to mistranslation in mammalian cells [31,
49, 50]. We hypothesized that the human tRNAGly and tRNAAla variants will cause
mistranslation of Gly codons with Ala and lead to defects in protein synthesis. To test this
hypothesis, mCherry was co-expressed as a marker for protein production from a plasmid
also bearing a wild-type or mutant tRNA allele. We recently showed that the human
tRNASerAGA (Ser-AGA-2–3 gene) G35A variant (tRNASerAAA) caused serine misincorporation at phenylalanine codons and inhibited protein synthesis in N2a cells [31].
Here, we employed tRNASerAAA derived from the Ser-AGA-2–5 gene as a positive control
to cause greater levels of mistranslation in cells. We co-expressed mCherry with
tRNASerAGA or tRNASerAAA in N2a cells and measured mCherry fluorescence (Fig. 2A,B).
N2a cells expressing the mutant tRNASerAAA showed a substantial and significant decrease
in mCherry fluorescence per cell compared to cells expressing the wild-type tRNASerAGA.
The data are in agreement with previous results from our lab [31], confirming a significant
tRNASerAAA-dependent reduction in protein synthesis in N2a cells.
We used the same approach to evaluate each of the wild-type and variant tRNAGly or
tRNAAla pairs (Table 1) for their impact on mCherry production. Thus, mCherry
fluorescence per cell was recorded in cells expressing the wild-type tRNA (tRNAAlaAGC or
tRNAGlyG/CCC) or their respective variants (tRNAAlaACC or tRNAGlyG/CCC A3G:U70) with
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the potential to decode Gly codons with Ala. The variant tRNAAlaACC, tRNAGlyGCC A3G,
and tRNAGlyCCC A3G each showed no significant change in mCherry fluorescence
compared to cells expressing the wild-type tRNA counterpart. Western blotting confirmed
these observations (Fig. 2C,D). While tRNASerAAA caused a significant decrease in
mCherry protein levels, none of the tRNAAla or tRNAGly variants led to a significant change
in mCherry protein levels.
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Figure 2: Protein synthesis levels in normal and mistranslating cells. (A) Brightfield
and fluorescent images showing mCherry production in cells co-expressing wild-type or
the indicated tRNA variants; (B) quantitation of mean mCherry fluorescence per cell. (C)
Western blot of mCherry and a GAPDH loading control and (D) quantification of fold
change of mCherry protein levels normalized by GAPDH. Independent sample t-tests were
computed (n.s. – not significant, *** = p  0.001, **** = p  0.0001) based on at least N
= 3 biological replicates.

Figure 2
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3.3

Cytotoxicity in mistranslating N2a cells

Previous work established toxicity resulting from mistranslating tRNAs expressed in
mammalian cells [49, 51], including from the tRNASerAAA variant employed here [31] . In
contrast, other mistranslating tRNAs elicit no cytotoxicity and are well tolerated in human
cells [37, 49-51]. We confirmed a significant increase in cytotoxicity in cells expressing
the mutant tRNASerAAA compared to the wild-type tRNA allele (tRNASerAGA) in N2a cells
(Fig. 3), while none of the tRNAAlaACC or tRNAGlyG/CCC A3G:U70 variants caused a
significant change in cytotoxicity compared with the wild-type tRNA allele (Fig. 3).
Interestingly, cells expressing any of these wild-type tRNAs or their potential
mistranslating variants showed relatively less cell death than cells expressing either of the
wild-type or variant tRNASer.

**

relative cell death (%)

25
20

n.s.
n.s.

15

n.s.

10

tRNA:

5
0

anticodon:
mutation:

Ser

Ser

Ala
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Gly

Gly

Gly
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AGA AAA AGC ACC CCC CCC GCC GCC
-

G35A
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G35C

-

A3G

-
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Figure 3: Cytotoxicity in N2a cells expressing wild-type or mistranslating tRNA
variants. Quantification of cytotoxicity (Cytotox-Glo) observed in N2a cells expressing
wild-type or the indicated tRNA variant. The tRNASerAGA 2–5 gene G35A variant
(tRNASerAAA) causes mis-incorporation of Ser at Phe codons [31] and significant toxicity
in N2a cells. The tRNAAla and tRNAGly variants caused no significant changes in toxicity
compared to cells expressing the wild-type counterpart. Independent sample t-tests were
computed (n.s. – not significant, ** = p  0.01) based on at least N = 3 biological replicates.
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3.4

Mass spectrometry identification of Ala mistranslation at Gly
codons

Although under normal conditions the tRNAAla and tRNAGly variants did not show
detectible changes in protein synthesis or cytotoxicity, we used mass spectrometry to
identify mis-incorporation in mCherry caused by the tRNAAlaACC variant and the
tRNAGlyGCC A3G mutant. As a control, mCherry was isolated from cells expressing wildtype tRNAAlaAGC. LC-MS/MS analysis of mCherry proteins purified from cells expressing
potentially mis-translating tRNAs revealed abundant evidence of Ala mis-incorporation at
multiple Gly codons.
In all transfected cells, we identified peptides indicating Ala mis-incorporation at G73,
G107 and G108. The peptide hits at G73 may represent a fragmentation product of the
cyclized red fluorophore, which is composed of residues M71, Y72, and G73. We also
identified a consistent signal for mis-incorporation of Ala at positions G107 and G108 in
all cells. Finally, in the wild-type tRNA-expressing cells, we found just one peptide each
supporting mis-incorporation at positions G121 and G196 (Fig. 4A, S1, Table 2).
Compared to peptides identified in cells expressing mutant tRNAs (Fig. 4, Table 2), peptide
quality scores [52] were generally lower in the wild-type cell line (-10logP = 30 - 46),
indicating greater uncertainty in the match of peptide to spectrum. Thus, these spectra may
represent natural Ala mis-incorporation at Gly codons, a methylation at a nearby site, or a
mis-identification of the peptide, which is also suggested by the low peptide quality scores.
Cells expressing the tRNAAla or tRNAGly mistranslating variants showed ample evidence
of Ala mis-incorporation at multiple Gly codons in mCherry. Gly sites that showed a
greater level of mis-incorporation (>1% ion intensity) were annotated with a small and red
boxed ‘g’ symbol above the sequence (Fig. 4, C1-C3). Nearly all mistranslated peptide hits
in the wild-type tRNA-transfected cells were less than 1% of the maximal ion intensity
(Fig. C1, 4A,B), indicating a low background level of potential Ala mis-incorporation. In
contrast, cells expressing the tRNAAla (Fig. 4C,D, S2) or tRNAGly (Fig. 4E,F, C3) variants
demonstrated evidence of mis-incorporation at several different Gly residues, supported by
multiple and high-quality peptide hits observed at >1% ion intensity. While we saw some
evidence of mistranslation at 4 of the 25 Gly sites in wild-type cells, cells expressing the
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tRNAAlaACC variant showed strong evidence of mistranslation at 7/25 Gly sites, and in cells
expressing the tRNAGly A3G variant we found Ala at 15/25 Gly residues (Fig. 4, C1-C3,
Table 2). The peptide to spectra match quality scores were higher in cells expressing
tRNAAla and tRNAGly variants compared to wild-type tRNA (Table 2). The higher ion
intensity and higher quality scores of peptides from cells expressing the mutant tRNAs
indicate confident identification of mistranslated peptides.
The mCherry construct contains nearly all GGC Gly codons and only one other Gly codon
(GGU). In addition to ample evidence of mistranslation at GGC, we also observed Ala misincorporation at G56 (GGU). We detected peptides at G56, suggesting Ala misincorporation as a result of variant tRNA expression (Fig. C4). However, the ion intensities
at these sites were less than 1% of maximal (Fig. C2, C3), suggesting relatively lower
abundance of the G56A peptide. Cells expressing tRNAAlaACC showed two independent
peptide hits that identify Ala at G56 (Fig. C2, C4A) albeit with a lower quality score (10logP = 38.8). Cells expressing tRNAGlyGCC A3G showed stronger evidence (-10logP =
58.5) of mis-incorporation at G56 (GGU) (Fig. S4B), and the same peptide indicated a
double mis-incorporation of Ala at both G56 and G57 (Fig S4B).
Interestingly, mistranslating cells expressing the tRNAGlyGCC A3G variant showed
additional evidence of double (Fig. C5A,B) and triple mis-incorporation events in
individual peptides from mCherry (Fig. C5C). In cells transfected with wild-type tRNA,
we recorded only a single peptide with dual mis-incorporation of Ala at G107, G108, with
ion intensity of less than 1%. Cells expressing tRNAGlyGCC A3G produced peptides
representing multiple dual mis-incorporation events at the same site (Fig. C3). We
identified peptide hits displaying dual Ala mis-incorporation at G106, G164 (Fig. C5A)
and at G175, G176 (Fig C5B).
Together the data demonstrate that both naturally occurring tRNAAlaACC and tRNAGlyGCC
A3G:U70 variants induce mistranslation of Ala at Gly codons. Thus, naturally occurring
anticodon or identity element mutations are viable routes to amino acid mis-incorporation
that is tolerated under normal conditions.
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Table 2: Summary of Ala mis-incorporation at Gly codons identified by MS/MS
tRNA gene

Ala-AGC-6-1

Ala-AGC-6-1

Gly-GCC-1-5

tRNA mCherry
variant residue
WT
G107A
WT
G108A
WT
G121A
WT
G196A
G35C
G5A
G35C
G73A
G35C
G107A
G35C
G108A
G35C
G138A
G35C
G160A
G35C
G196A
A3G
G5A
A3G
G29A
A3G
G95A
A3G
G107A
A3G
G108A
A3G
G121A
A3G
G138A
A3G
G147A
A3G
G160A
A3G
G164A
A3G
G175A
A3G
G176A
A3G
G196A
A3G
G224A
A3G
G229A
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maximal
-10logP
69.37
64.26
46.99
35.12
55.78
67.90
63.70
69.02
48.41
42.33
58.42
61.30
52.94
56.59
75.15
69.41
44.13
58.43
48.34
66.97
69.48
54.35
57.70
72.08
64.70
54.54

ion counts
Ala/Gly
3A/7G
3A/7G
1 A / 14 G
1 A / 17 G
2A/9G
5 A / 10 G
3 A / 10 G
3 A / 11 G
1A/6G
1A/8G
2 A / 18 G
4 A / 11 G
2 A / 16 G
5 A / 19 G
4 A / 15 G
5 A / 15 G
2 A / 29 G
1 A / 17 G
3A/7G
3 A / 18 G
3 A / 15 G
4 A / 18 G
5 A / 18 G
2 A / 28 G
2A/3G
1A/8G

A

B

g = G+14.02 = Ala

121

intensity (%)

G121A (-10logP) = 46.99

196

intensity (%)

G196A (-10logP) = 35.12

5

25

56

D
G5A (-10logP) =55.78

intensity (%)

C

138

196

160

intensity (%)

G196A (-10logP) = 58.42

E
5

29

95

121

138

F
intensity (%)

G95A (-10logP) = 56.59

160 164

175 176

224

G224A (-10logP) = 50.89
229

intensity (%)

147

m/z

Figure 4
Figure 4: tRNA-dependent mis-incorporation of Ala at Gly codons detected by mass
spectrometry. Tandem mass spectrometry analysis revealed alanine mis-incorporation in
mCherry isolated from N2a cells expressing (A, B) the wild-type tRNAAlaAGC; (C, D) the
tRNAAlaACC variant; and (E, F) the tRNAGlyGCC A3G variant. Mis-incorporation events in
mCherry (red boxed g = Gly + 14.02 = Ala) isolated from each cell line are depicted
alongside (B, D, F) example spectra from the identified peptides. Red boxed ‘g’ symbols
above peptide sequence annotate mistranslated residues identified with minimal ion
intensities of ≥ 1%.
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3.5

Protein synthesis in HEK 293T cells expressing wild-type or
mistranslating tRNAs

Previous studies suggest that tRNA gene expression profiles show both cell-type and
tissue-specific dependence [53]. Thus, we reasoned that differential expression of a
particular mistranslating tRNA variant, or of other tRNAs that the mutant tRNA competes
with for aminoacylation or decoding, may change the impact of the tRNA variant in
different cell lines. To test this, we assayed protein synthesis in HEK 293T cells expressing
wild-type or mistranslating tRNA variants. The mCherry fluorescence per cell in HEK
293T cells revealed an expected defect in protein synthesis in cells expressing the
tRNASerAAA variant (Fig. 5A,5C). In comparison to wild-type tRNA alleles, however, the
tRNAAlaACC or tRNAGlyG/CCC A3G:U70 variants showed no change in mCherry
fluorescence per cell in HEK 293T cells (Fig. 5A,5C), similar to our observations in N2a
cells described above.
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Figure 5: Proteasome inhibition reveals defective protein synthesis in cells expressing
tRNAGlyGCC A3G. Brightfield and fluorescence images showing mCherry fluorescence in
cells expressing wild-type or mistranslating tRNA variants in (A) 0 µM or (B) 10 µM
MG132. Quantitation of mean fluorescence per cell was plotted for cells treated with (C)
0 µM or (D) 10 µM MG132. Independent sample t-tests were computed (n.s. – not
significant, * = p  0.05, ** = p  0.01, *** = p  0.001) based on at least N = 3 biological
replicates.

Figure 5
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3.6

Cell-specific cytotoxicity of tRNA-dependent mistranslation

In N2a cells expressing tRNASerAAA, we observed significant cytotoxicity induced by Ser
mis-incorporation at Phe codons (Fig. 3). In contrast, we found no significant change in
toxicity in HEK 293T cells expressing tRNASerAGA versus tRNASerAAA (Fig. 6A).
Repression of protein synthesis in HEK 293T cells expressing tRNASerAAA (Fig 5A,C)
suggests that mistranslation occurs at a level that does not increase cell death (Fig. 6A).
The data indicate that the level of tRNA-dependent mistranslation or its associated
phenotypic defects may be cell specific. For each of the tRNAAla and tRNAGly variants, we
recorded no changes in cytotoxicity in HEK 293T cells (Fig. 6A), similar to our findings
in N2a cells above.

3.7

Mistranslation in the context of proteasome inhibition

Since mass spectrometry confirmed Ala mis-incorporation is caused by natural human
tRNAAla and tRNAGly variants, we hypothesized that additional stress on the cell could
reveal a phenotypic defect associated with Ala mis-incorporation at Gly codons. MG132
is a potent proteasome inhibitor [54] that we used previously to measure defects in protein
synthesis and protein degradation in cells expressing the mistranslating tRNASerAAA variant
[31]. We anticipated that inhibition of a major protein degradation pathway would cause
mis-made and mis-folded proteins to accumulate and disrupt protein homeostasis in
mistranslating cells.
HEK 293T cells expressing wild-type or mistranslating tRNAs were exposed to MG132
and mCherry fluorescence was measured as a marker for protein synthesis (Fig 5B,D).
Cytotoxicity was monitored to identify toxic genetic interactions between proteosome
inhibition and mistranslation (Fig. 6). In the presence of 10 µM MG132, both tRNASerAAA
and tRNAGlyGCC A3G variants lead to significantly decreased fluorescence of mCherry per
cell compared to cells expressing their wild-type tRNA counterparts. Interestingly, the
tRNAGlyGCC A3G and not the tRNAGlyCCC A3G variant caused a reduction of protein
synthesis in the context of proteasome inhibition (Fig. 5D). The tRNAAlaACC variant also
showed no further evidence of disrupted protein homeostasis in cells treated with MG132
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(Fig. 5B,D). Both the Phe-decoding tRNASerAAA and the Ala mis-incorporating tRNAGlyGCC
A3G showed significant inhibition of protein synthesis under proteasome inhibition
compared their wild-type tRNA counterparts.
Application of MG132 increased cell death in HEK 293T cells with each tRNA tested (Fig.
6A,B). However, we observed no apparent increase in cytotoxicity in cells expressing wildtype versus mistranslating tRNAAla or tRNAGly variants in the context of proteasome
inhibition. Even tRNAGlyGCC A3G, which showed defective protein synthesis in MG132
treated cells, was well tolerated in terms of cell toxicity. Interestingly, we observed a small
but significant reduction in cytotoxicity in HEK 293T cells expressing tRNASerAAA variant
compared to the wild-type tRNASerAGA under proteasome inhibition (Fig. 6B). This finding
contrasts the situation in N2a cells, which showed a strong synthetic toxic interaction
between tRNASerAAA expression and proteasome inhibition [31]. These data again indicate
cell-specific phenotypic defects associated with different mistranslating tRNAs.
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Figure 6: Proteasome inhibition reveals reduced toxicity from Ser mis-incorporation
at Phe codons but not from Ala mis-incorporation at Gly codons in HEK 293T cells.
Quantification of cytotoxicity (Cytotox-Glo) observed in HEK 293T cells in (A) standard
conditions or (B) following treatment with 10 µM MG132 proteasome inhibitor.
Independent sample t-tests were computed (n.s. – not significant, * = p  0.05) based on at
least N = 3 biological replicates.
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3.8

Protein synthesis and aggregation in mistranslating cells
expressing ALS-associated FUS protein

To assay the effects tRNA variants can have on protein aggregation associated with
disease, N2a cells were transfected with plasmids containing genes for either tRNASerAGA,
or the tRNASerAAA variant alongside mCherry, FUS-mCherry, or R521C FUS-mCherry.
Cells were grown for 72-hours to ensure aggregate development before cell harvest and
lysis. Western blot analysis revealed a decrease in protein production resulting from
tRNASer G35A mutant expression in both wild-type and mutant-FUS expressing cells,
compared to wild-type tRNASer expression in a similar context (Fig. 7A). Semi-denaturing
gel electrophoresis (SDD-AGE) was performed to determine the amount of protein
aggregated in different conditions. The wild-type tRNASer did not affect the amount of
wild-type or R521C mutated FUS aggregation, but tRNASerAAA significantly reduced the
amount of protein that was aggregated. The mutant FUS R521C was significantly more
aggregated in mistranslating cells compared to the wild-type FUS allele when expressed
alongside the mistranslating tRNASerAAA.
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Chapter 4

4

Discussion

4.1

Mistranslation from natural tRNAAla and tRNAGly variants in
human cells

The human genome contains a diverse and large family of tRNAs, encoding more than 600
tRNA genes [39]. Although some tRNA genes may be pseudogenes, estimates indicate at
least 400 tRNA genes are ‘high confidence’ or likely functional tRNAs [55]. Evidence
from human serum samples suggests expression of 411 different tRNA genes, and the
human liver alone expresses at least 224 different tRNA genes [56]. A recent approach
based on experimental data and sequence properties of tRNA genomic loci predicted that
at least 314 tRNAs are functional and expressed [57]. Different human cells and tissues
show differential regulation of tRNA genes [53, 58, 59], which include tRNAs for each
proteogenic amino acid and many copies of each tRNA isoacceptor. Even tRNA
isodecoders that share the same anti-codon are found in multiple copies. For example, the
human tRNAGly genes include 28 high confidence genes, using one of three anticodon
sequences (5’-G/C/UCC-3’) to decode four (5’-GGN-3’) glycine codons. The human
tRNAome contrasts those of yeast (275 tRNAs) and E. coli (88 tRNAs), which have much
smaller genomic copy numbers of tRNAs. Human tRNAs are also more diverse than their
counterparts in yeast [24]: the diversity of human tRNA genes is not confined to the
differences between tRNA isodecoders in a single genome, but rather each individual
harbours between 60 to 70 single nucleotide polymorphisms in their tRNA genes compared
to the reference genome [23].
Some of these variants produce tRNAs that are likely to misread the genetic code and cause
mistranslation that affects the entire proteome. While some mistranslating tRNA variants
are found in exceeding rarity (1 to 2 examples per 100,000 genomes), other tRNAs that
cause or may cause mistranslation are found as common variants in the population, with
mean allele frequencies in excess of 5%. We previously characterized [31] and here
provided additional data regarding a tRNASerAGA G35A variant that mis-incorporates Ser
at Phe codons. The tRNASerAAA variant occurs in 2-3% of the population [23, 24], yet some
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potential tRNA mistranslators are also found in up to 8.5% of the population, such as the
tRNAAla and tRNAGly variants we characterized here (Table 1). These variants represent
two different mechanisms by which a tRNA can gain function to mis-incorporate amino
acids. In the case of tRNAAla, the anticodon mutation is ignored by AlaRS, and the resultant
Ala-tRNAAlaACC decodes Gly codons. In contrast, the tRNAGly A3G variants contain an
AlaRS identity element, G3:U70 [33], which leads to Ala-tRNAGly synthesis and decoding
of Gly codons with Ala. Our observations here, together with our previous study of a
human tRNAPro G3:U70 variant [37], demonstrate that AlaRS can misaminoacylate
different kinds of tRNA variants that create a G3:U70 base pair and cause Ala
misincorporation in mammalian cells.
A recent study [60] focused on a similar kind of naturally occurring tRNA variant that
creates a G4:U69 base pair, which is sufficient to confer Ala-accepting activity [61], in
different tRNAs, including threonine (Thr) tRNAs. Although human AlaRS produces AlatRNAThr when the G4:U69 variant is present, the threonyl-tRNA synthetase (ThrRS) found
in mammalian cells and murine tissues possesses deacylation activity towards the
mischarged Ala-tRNAThr, apparently preventing mistranslation [60]. We can confirm that
no similar activity is found in mammalian (N2a) cells to proofread Ala mischarging of
tRNAs that read Gly codons. Overall, our findings demonstrate that common tRNA
variants can cause mistranslation of a kind or a level that cells are able to tolerate under
normal conditions.

4.2

Amino acid similarity may alleviate mistranslation toxicity in
cells

Here I compared a tRNASer variant that mistranslates Phe codons and a series of tRNA
variants that misread Gly codons with Ala to their respective wild-type tRNAs. In terms of
their chemical similarity in solution or in the context of a folded protein, Gly and Ala are
much more similar amino acids than Phe and Ser. In agreement with this, I observed
significant cytotoxicity only in cells expressing the Phe-decoding tRNASer variant, while
the tRNAAla and tRNAGly variants lead to no changes in cytotoxicity, despite showing
strong evidence of amino acid misincorporation.
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Several examples in the literature support the idea that the similarity between an intended
versus a mis-incorporated amino acid is an important factor impacting the degree and
severity of cellular response to mistranslation, including resulting phenotypic defects in
mistranslating cells. In yeast, tRNASer variants were assayed for the ability to misread Arg
codons, along with characterization of tRNAPro variants that misread Pro codons with Ala
[62]. Ser mistranslation at Arg codons induced production of heat shock proteins and
showed a greater decrease in growth rate compared to yeast cells that substituted Ala at Pro
codons. Thus, the nature or similarity of mis-incorporated amino acids will impact the
cellular response and the level of toxicity associated with mismade proteins.
Previous work in mammalian cells addressed the similarity of ambiguously encoded amino
acids in the context of Ser misincorporation. A series of chimeric or synthetic tRNASer
variants with several different anticodons were expressed in mammalian cells. Each variant
caused Ser misincorporation at codons for several different amino acids [49]. Key evidence
on the impact of mistranslation was found by surveying GFP production and fluorescence
in HEK 293T cells, similar to our approach using mCherry as a marker of protein synthesis.
Cells that mis-incorporated Ser at Lys codons showed only a minimal defect, while Ser
mis-incorporation at Ile codons displayed the greatest defect in protein synthesis. In terms
of severity of the phenotypic defect, cells mistranslating Ser for a group of amino acids
showed increasing reductions in protein synthesis (Lys < Gln < Asn < Arg < Tyr < Pro <
Glu < His < Asp) between 95% and 60% of wild-type levels. A tRNASer with an Ile
anticodon reduced GFP levels to 20% of that in cells expressing a wild-type tRNASer. We
found that the tRNASerAAA variant reduced mCherry levels per cell to 70% or 84% of that
in N2a or HEK 293T cells expressing the wild-type tRNA, respectively. Under normal
conditions, tRNAAla and tRNAGly variants had no effect on mCherry levels, while
proteasome inhibition in HEK 293T cells reduced mCherry levels in cells expressing
tRNAGlyGCC A3G to 85% of that in cells expressing the wild-type tRNAGly. Thus, these
data suggest that Ala misincorporation at Gly codons is less disruptive to protein
homeostasis than Ser misincorporation at Phe codons.
The rate or level of mistranslation can also contribute to toxicity or growth defects
associated with mistranslation [45, 63]. Two synthetic tRNA variants, one that causes more
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frequent errors with Ser misincorporation at Ala codons and another that causes less
frequent Ser mistranslation at Leu codons, were characterized in murine NIH3T3 cells [51].
Although both tRNA variants were well tolerated in cells, the Ser-tRNAAla mistranslator
stimulated the protein kinase B (AKT) cell survival pathway and increased the growth rate
of tumor cells injected into mice. The lower frequency mistranslator and less conservative
Leu to Ser substitution was indistinguishable from a control lacking additional tRNA.
Another factor that can influence the level of mistranslation is related to how many codons
are effectively read by a mistranslating tRNA. The tRNAAlaACC variant characterized here
contains an A34, which is normally converted to inosine (I34) [64]. The I34 base is capable
of superwobble and can read U, C, and A codons [65]. The fact that this tRNA decodes
multiple GGC codons as Ala suggests the I34 modification is intact. The mCherry construct
contains only one other Gly codon (GGU), and I found evidence that both tRNAAla and the
tRNAGly variants direct Ala misincorporation at G56 of mCherry (GGU) (Fig. C4A). In
on-going studies, we are working towards quantitative methods relying on mistranslationsensitive fluorescent reporters [45] and absolute quantitation approaches with massspectrometry [66] to accurately establish the level of Ala misincorporation at Gly codons.
In our future work, these approaches will also allow us to quantify the level of Ala
misincorporation at each of the four Gly codons.

4.3

Cell viability and protein homeostasis despite low fidelity
translation

We are only at the beginning of understanding human tRNA variants and their ability to
cause mistranslation or impact health and disease [24]. Indeed, the relative abundance of
some tRNA variants in the population, such as the common tRNAGly and tRNAAla variants
characterized here, suggests that some mistakes in protein synthesis are less harmful than
others and that our cells are robustly insensitive to significantly elevated levels of error in
protein synthesis. Initial proposals, including Crick’s frozen accident [67] and Orgel’s error
catastrophe hypothesis [68], envisioned the proteome as a fragile entity that is intolerant to
errors. Crick’s theory considered changes to standard genetic code or ambiguous decoding
of codons as a phenotype that would most certainly be selected against during evolution.
Since that time, many changes to the genetic code have been identified in natural species,
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and changes to codon assignments most often require evolution of tRNA variants [69].
Indeed, the yeast Candida albicans decodes CUG codons ambiguously as Ser (97%) and
Leu (3%) as a result of an atypical tRNASerCAG that is recognized by both leucyl-tRNA
synthetase (LeuRS) and SerRS [70].
Orgel’s theory [68] suggests that low fidelity translation would be fatal to cells. This error
catastrophe theory proposes that protein synthesis machinery produced from a low fidelity
system would increasingly accumulate errors to the point where the protein components of
the translation apparatus themselves would no longer function. Thus, low fidelity
translation would lead to the inability to produce the proteins needed to support life. In
cells expressing a natural tRNASerAAA variant, mistranslation can be toxic [31] or, in the
extreme limit, high levels of misincorporation can inhibit cell viability [71, 72]. However,
cells from the many diverse forms of life maintain viability even in the context of
dramatically increased levels of amino acid misincorporation [37, 73]. In E. coli, several
missense suppression systems, including those that substitute Cys at Pro codons, Ser at Thr
codons, Glu at Gln codons, and Asp at Asn codons, all showed negligible impacts on cell
growth. Protease deficient E. coli strains, however, showed strong and differential
sensitivity to each kind of mistranslation [74], demonstrating the importance of a protein
quality control mechanism to mitigate the impact of low fidelity translation. In other
contexts, including under conditions of oxidative or chemical stress, amino acid
misincorporation can be beneficial or provide a selective advantage to bacterial [75], yeast
[73], and mammalian cells [76]. In the case of Ala misincorporation at Gly codons in
human cells, my data affirm the robust nature cells have to prevent mistakes in protein
synthesis.

4.4

Protein aggregation in mistranslating cells

To assay the effects of mistranslation on protein aggregation, I expressed the tRNASerAAA
variant alongside ALS-causing R521C mutant FUS protein in N2a cells. tRNASerAAA was
previously reported to increase aggregation of a non-aggregating HTT protein and decrease
the aggregation of mutant HTT protein [31]. Cells expressing the tRNASerAAA variant were
also defective in degradation of HTT protein aggregates following treatment with a
detergent to resolve the aggregates [31]. Here we found the mistranslating tRNASerAAA
31

decreased the aggregation of both wild-type and R521C mutant FUS protein. These results
are consistent with the overall decrease in protein synthesis observed in mistranslating cells
caused by tRNASerAAA expression shown previously [31]. The combination of misfolded
protein aggregation and mistranslation is likely overwhelming protein turnover machinery
in cells, therefore stalling translation altogether, in an attempt to clear the aggregates. It
was further previously reported that mistranslating cells have slowed protein turnover rates
and stalled ribosomal translation [31]. Stalled translation and defective protein degradation
contributes to the increased toxicity and decreased protein production witnessed in
mistranslating cells, regardless of protein aggregation.
Future studies will elucidate the mechanisms leading to decreased protein synthesis and
increased cytotoxicity between mistranslating tRNAs and protein aggregation associated
with ALS. We will next determine the rate of mistranslation, examine ribosome stalling
events, and assay for other pathways of protein turnover activation (autophagy).

4.5

Impacts of mistranslation on mCherry fluorescence

Three-dimensional folded protein structure is likely predetermined by the primary amino
acid sequence of a protein since each amino acid has different chemical properties that
influence their placement within a protein [77]. For example, Ser contains a polar hydroxyl
group, meaning it can interact with water molecules within the cell and is therefore often
found on the outer surface a folded protein. In contrast, Phe is almost always found within
the core of a protein due to its hydrophobic nature and aromatic ring structure. Thus, in
general, polar amino acids are often situated on the surface of proteins to facilitate
interactions with polar environment, while non-polar amino acids tend to be folded tightly
towards the inside of proteins to ensure protein stability [78]. Due to the structural and
functional differences between the amino acids, mistranslation of Phe to Ser caused by
tRNASerAAA resulted in the dimming of mCherry that was observed (Fig. 2B), likely caused
by impaired chromophore maturation or decreased tightening of the protein core [79].
Furthermore, mistranslation causes slowed protein production [49, 50], meaning that
expression of the tRNASerAAA variant led to the decrease in protein levels observed (Fig. 2
C).
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In contrast to Phe to Ser mistranslation events, the impact of Gly to Ala mistranslation was
not severe. The chromophore of mCherry is made up of three residues – methionine,
tyrosine, and glycine (Fig. D1 C). Although Gly is part of the chromophore, mass
spectrometry did not reveal strong evidence to conclude mistranslation at Gly 73. Further,
the population of mCherry that had a Gly73Ala mistranslation did not suffer functionally,
as no decrease in fluorescence was observed when mistranslating tRNAs were expressed.
The lack of a side chain on Gly allows for high flexibility of the residue, leading to
complete 360-degree range of motion, where other amino acids are more rigid in structure.
The flexibility of Gly plays a role in creation of turning segments of protein beta-sheet
secondary structure and is a large part of fluorescent proteins that exhibit a beta barrel 3-D
conformation (Fig. D1 A,B) [80]. Gly is also found within some enzyme active sites,
allowing the enzyme to change conformation more easily when unbound vs. bound to its
substrate [81]. Mistranslation of Gly will always place a larger and potentially bulkier
amino acid in its place as it is the smallest amino acid. These substitutions may hinder a
protein’s ability to fold and function correctly due to the loss of flexibility associated with
other amino acids. However, we observed no impact of Gly mistranslation within mCherry,
likely due to the conservative nature of the amino acid misincorporation (Gly to Ala). Ala
only differs to Gly by one additional methyl group. The difference between side chains is
relatively minor, does not prompt any new bond formations within the protein, and, as far
as we could tell, did not hinder the ability of mCherry to fold and function as normal.
Overall, some amino acid substitutions are not as harmful as others when examining
protein function (Gly to Ala vs. Phe to Ser), allowing the protein to function as if it were
the wild-type protein. Future studies will look to achieve a more global understanding of
how Gly to Ala mutations may affect the cell by examining glycine-rich cellular proteins
such as collagen through a scratch assay. If Gly to Ala mistranslation alters collagen
function, this would allow us to determine any impacts of that mistranslation by studying
the cellular migration. As well, mass spectrometry of total cellular proteins as opposed to
solely mCherry may reveal a more accurate level of mistranslation occurring globally in
the cell as a result of variant tRNA expression.
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5

Conclusion

5.1

Glycine to alanine mistranslation is not toxic in mammalian
cells

I found that naturally occurring human tRNAAla anticodon and tRNAGly identity element
variants are both viable routes to Ala misincorporation at Gly codons. These variants occur
commonly in the human population, and while they cause mistranslation verified by mass
spectrometry, their impact on cells under normal conditions is minimal. Thus, human cells
are robust with respect to Ala misincorporation at Gly codons, suggesting that tolerance to
mistranslated proteins allows for the propagation of these variants in the population. One
mutant showed defective protein synthesis only in the context of inhibited protein
degradation, suggesting that the accumulation of mis-made protein caused defects in
protein synthesis. Our data demonstrate natural tRNAs that mistranslate Gly codons with
Ala have the potential to impact cell health under conditions of stress.

5.2

Mistranslation can modify protein aggregation

I examined the effects a mistranslating tRNASer can have on protein aggregation in cells
using a model of ALS caused by a mutant FUS protein. I found that expression of
tRNASerAAA significantly increased the amount of aggregation of the ALS-causing R521C
FUS mutant compared to the wild-type protein, but reduced global aggregation compared
to expression of the wild-type tRNASerAGA. As well, we reported that co-expression of the
mistranslating tRNA and disease-causing FUS allele reduced protein synthesis and
aggregation, while increasing toxicity (Lant et al, under review). We demonstrated the
ability of a mistranslating tRNA to exacerbate disease phenotypes in mammalian cells.
Future work will look to elucidate the mechanism of action between the mistranslating
tRNA and the aggregating protein in order to better understand the synergistic effects seen
in this study.

5.3

Mistranslation impacts proteostasis

Mistranslation of Phe to Ser caused by tRNASerAAA altered protein levels within the cell by
slowing protein synthesis, and reduced mCherry fluorescence due to improper
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chromophore maturation. As well, a decrease in protein turnover caused by tRNASerAAA
mistranslation was reported in a previous study [31]. Although it is possible that
mistranslation of all Gly residues with Ala could have resulted in similar fluorescence
dimming of mCherry, our model for tRNA-dependent mistranslation was not strong
enough to induce complete mistranslation within the protein. Thus, we concluded that the
Gly to Ala mistranslation observed did not impact mCherry function and was not toxic to
the cells.
Despite deleterious effects on protein fluorescence and cell toxicity observed in this study,
mistranslation in cells is not avoidable, but can be beneficial under certain circumstances.
Under conditions of oxidative stress, mammalian cells have been observed to increase misaminoacylation of Met onto non-cognate tRNAs by MetRS [82]. Methionine incorporation
in proteins aids in the oxidative stress response as Met has antioxidant properties due to its
redox ability [83]. As well, mistranslation within cells under stress conditions provides an
avenue for sampling different functional protein conformations. By way of incorporating
incorrect amino acids into proteins, the cell may improve protein stability, modify protein
function, or strengthen stress responses in an attempt to diversify the proteome to function
outside of the wild-type environment [84, 85].

5.4

Significance

We now know that humans have a greater number of tRNA gene variants in their individual
genomes than previously recognized [23, 24, 39], some of which have the ability to cause
protein mistranslation, yet they remain largely uncharacterized. It is important to study
mistranslating tRNA variants as they lay the foundation for appropriate translation of
proteins and maintenance of cellular function. tRNAs are essential to the translation of
proteins, and high rates of mistranslation have the potential to be deleterious and modify
disease severity. Understanding tRNA variants is important for determining their role in
health and disease, as well as opening avenues for tRNAs as therapeutics for nonsense [86]
and eventually missense suppression.
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5.5

Future Directions

Future experiments will elucidate the effects of tRNA-dependent mistranslation on protein
degradation through a cycloheximide chase assay while protein synthesis rates will be
measured by a puromycin incorporation assay. As well, future work for this project will
examine the impact of Ala mistranslation at Gly codons on mammalian cells in the context
of an aggregating protein model of ALS and HD under normal and stress conditions.
Further, this mistranslation could serve as a potential rescue for diseases caused by Ala to
Gly misincorporation. Finally, I will be using CRISPR/Cas9 editing to create a stable
mistranslating cell line that will allow for more effective examination of mistranslation in
a native context, providing an avenue for assaying native cellular stress responses to tRNAdependent mistranslation in mammalian cells. Otherwise, cell samples from individuals
that naturally have these mistranslating tRNA variant genes in their genomes may also be
acquired from the Coriell Institute Biobank. The cell samples will be assayed for the
presence of the tRNA genes by genomic PCR amplification and the impacts expression of
the variant tRNAs have in a true native context.
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Appendices
Appendix A: Plasmids

Figure A1: pPan-Cherry plasmid map. Depiction of the pPan-Cherry plasmid used in
this study. tRNASerAGA is shown between two PciI restriction sites where tRNA genes were
cloned into the plasmid. tRNA genes were cloned to include ~300 bp of up- and
downstream sequence to ensure transcription factor binding sequences and internal
promoters were conserved for appropriate transcription by RNA polymerase III.
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Figure A2: FUS plasmid map. Map of plasmid used in this study to express FUS fused
to mCherry protein for visualization using the EVOS microscope. Wild-type or G35A
mutant tRNASer were cloned into the plasmid using the PciI restriction site depicted.
Location of the R521C mutation in FUS is highlighted.
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Appendix B: Primers
Table B1: List of primers used to construct tRNA variants
tRNA gene

tRNAAlaAGC

Primer Name

Sequence (5’-3’)

Experimental Use

F-tA-AGC-6-1-Rnd1

AAATCAGTTATTTCAATGGGG

R-tA-AGC-6-1-Rnd1

ACTATGTGGGTCTCTAATGG

Genomic PCR of 500
bp up- and downstream
of tRNA sequence

F-tA-AGC-6-1-Rnd2-PciI

CAGACTACATGTAGAGAATGTTGTATGCCAGG

R-tA-AGC-6-1-Rnd2-PciI

CAGACTACATGTTTAGTGATTGGTGGACTGC

F-tA-AGC-6-1-G35C

TGCTTACCATGCACGAGGTCCTG

R-tA-AGC-6-1-G35C

CGTGCATGGTAAGCACGCGCTCTAC

F-tG-CCC-1-1-Rnd1

AAAAGACTAACTTAGTGGACC

R-tG-CCC-1-1-Rnd1

TCTCCACGCAGATTCTTGC

F-tG-CCC-1-1-Rnd2-PciI

CAGACTACATGTGTTGACGATGGAAGATTTAGG

R-tG-CCC-1-1-Rnd2-PciI

CAGACTACATGTGTTCTTCGGGTTTGCAGG

F-tG-CCC-1-1-A3G

CAGAGGCGTTGGTGGTTCAGTGGTAG

R-tG-CCC-1-1-A3G

CCACCAACGCCTCTGCGTAACAACC

F-tG-GCC-1-5-Rnd1

TAGCAATACTTCAAGTGACC

R-tG-GCC-1-5-Rnd1

TAAAGCAAGGTCCTCAGGC

F-tG-GCC-1-5-Rnd2-NcoI

CAGACTCCATGGGCAAACTCCAGATGGCTG

R-tG-GCC-1-5-Rnd2-NcoI

CAGACTCCATGGAGTAGCTGGGACTACAGGC

F-tG-GCC-1-5-A3G

CGGTGCGTGGGTGGTTCAGTGG

R-tG-GCC-1-5-A3G

CACCCACGCACCGATAGAAGAGTTG

6–1

tRNAGlyCCC 1–1

tRNAGly

GCC

1–5

X – mutated residue
X (bold) – restriction enzyme cut site
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PCR to add the correct
restriction site to ends
of sequence for
plasmid ligation
SOE PCR to generate
mutant tRNA variant
Genomic PCR of 500
bp up- and downstream
of tRNA sequence
PCR to add the correct
restriction site to ends
of sequence for
plasmid ligation
SOE PCR to generate
mutant tRNA variant
Genomic PCR of 500
bp up- and downstream
of tRNA sequence
PCR to add the correct
restriction site to ends
of sequence for
plasmid ligation
SOE PCR to generate
mutant tRNA variant

Appendix C: Mass Spectrometry

Figure C1: Peptide coverage map of mCherry produced in and isolated from cells
expressing wild-type tRNAAlaAGC. MS/MS spectra supporting Ala mis-incorporation at
Gly codons in mCherry were identified using PEAKS software [52] as a modified Gly
(lower case g, Gly + 14.02 = Ala). Red boxes around lower case “g” symbols indicate the
location of glycine to alanine mistranslation in the identified peptides. Red boxed ‘g’
symbols above peptide sequence annotate mistranslated residues identified with minimal
ion intensities of ≥ 1%.

Figure S1
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Figure C2: Peptide coverage map of mCherry produced in and isolated from cells
expressing the tRNAAlaAGC G35C variant. MS/MS spectra supporting Ala misincorporation at Gly codons in mCherry were identified using PEAKS software [52] as a
modified Gly (lower case g, Gly + 14.02 = Ala). Red boxes around lower case “g” symbols
indicate the location of glycine to alanine mistranslation in the identified peptides. Red
boxed ‘g’ symbols above peptide sequence annotate mistranslated residues identified with
minimal ion intensities of ≥ 1%.

Figure S2
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Figure C3: Peptide coverage map of mCherry produced in and isolated from cells
expressing the tRNAGlyGCC A3G mutant. MS/MS spectra supporting Ala misincorporation at Gly codons in mCherry were identified using PEAKS software [52] as a
modified Gly (lower case g, Gly + 14.02 = Ala). Red boxes around lower case “g” symbols
indicate the location of glycine to alanine mistranslation in the identified peptides. Red
boxed ‘g’ symbols above peptide sequence annotate mistranslated residues identified with
minimal ion intensities of ≥ 1%.

Figure S3
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A
intensity (%)

G56A (-10logP) = 38.80

m/z

B
intensity (%)

G56A (-10logP) = 58.51

m/z

Figure C4: Tandem mass spectra documenting Ala mis-incorporation at Gly56
(GGU). MS/MS spectra for peptides demonstrating Ala misincorporation at Gly56 (GGU)
in mCherry isolated from (A) N2a cells expressing mutant tRNAAlaAGC G35C or from (B)
cells expressing mutant tRNAGlyGCC A3:G70.
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G160A (-10logP) = 47.37

G164A (-10logP) = 47.37

intensity (%)

intensity (%)

A

m/z

G175A (-10logP) = 35.37

G176A (-10logP) = 35.37

intensity (%)

intensity (%)

B

m/z

m/z

G107A (-10logP) = 30.38

G108A (-10logP) = 30.38

intensity (%)

intensity (%)

C

m/z

m/z
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intensity (%)

G121A (-10logP) = 30.38

m/z

Figure C5: Tandem mass spectra of double and triple mistranslated Gly codons in
individual peptides. The spectra show double or triple Ala misincorporation events at Gly

Figure S5

residues in the same mCherry peptide isolated from N2a cells expressing the mistranslating
tRNAGlyGCC A3G:U70 mutant. The spectra support double mis-incorporation at (A) Gly
residues 160 and 164 and (B) Gly residues 175 and 176. Triple mis-incorporation was
identified in a peptide containing Ala at (C) Gly residues 107, 108, and 121.
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Appendix D: Structure of mCherry

A

B

C

Figure D1: Protein structure of mCherry and its chromophore. 3D depiction of the
protein structure of mCherry from the side (A) and from the top (B). All glycine residues
are shown in both views of the structure. The mCherry chromophore (C) is depicted with
the 3 residues listed. Carbon atoms are shown in light blue, oxygen atoms are shown in
red, nitrogen atoms are shown in dark blue, and sulphur atoms are shown in yellow. The
image was made using VMD [87]; mCherry PDB ID: 2H5Q [88].
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